Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer

Fig. 4

Ex vivo validation of [89Zr]Zr-cetuximab PET imaging. Protein/GAPDH ratios obtained from densitometric analysis of western blots of MDA-MB-231 tumors (a). Analysis of [89Zr]Zr-cetuximab uptake in tumors (%ID/g) plotted against their corresponding total EGFR/GAPDH ratio displayed a direct association of the tumor uptake of the tracer with EGFR expression (b). Densitometry analysis of MDA-MB-468 lysates (c). A positive correlation was achieved between total EGFR/GAPDH and tumor uptake of the tracer (%ID/g) (d)

Back to article page